Chi­na work­ing on con­ces­sions to help home­grown com­pa­nies stay on US ex­changes — re­port

As the threat of delist­ing rat­tles a num­ber of US-list­ed Chi­nese com­pa­nies — in­clud­ing some promi­nent drug­mak­ers — Chi­na is re­port­ed­ly con­sid­er­ing some con­ces­sions to make things eas­i­er for those home­grown play­ers.

Hutchmed, BeiGene and Zai Lab were among the com­pa­nies called out by the SEC a few days ago for po­ten­tial­ly vi­o­lat­ing a new law that came in­to ef­fect last year, which stip­u­lates that com­pa­nies can be delist­ed if their fi­nan­cials are au­dit­ed by a firm that can­not be re­viewed by US in­spec­tors. Chi­nese laws cur­rent­ly pro­hib­it for­eign ac­cess to such in­for­ma­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER